New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon announced data from a Phase 3 trial evaluating teprotumumab for active thyroid eye disease, which often occurs in people with Graves’ disease.